In our previous animal or in vitro studies, the extract of goshajinkigan has the ability to reduce sarcopenia symptoms in senescence-accelerated mouse P8 [7], to ameliorate allodynia in chronic constriction injury model mice [8] and in streptozotocin-induced diabetic model mice [9], and to suppresses voltage-gated sodium channel Nav1.4 current in murine myoblast C2C12 cells [10] and Nav1.7 current in HEK293 cells expressing Nav1.7 [9]. The gene discussed is SCN9A; the disease is sarcopenia.